Semaglutide Anti-Aging Health Benefits
Semaglutide isn’t just effective for losing weight, semaglutide anti-aging benefits are huge. Its other potential anti-aging benefits include:
- Improved endothelial function (heart/blood vessel lining for better blood flow and reduced heart attack/stroke risk)
- Reduced atherosclerosis. Atherosclerosis refers to the dangerous thickening/hardening of the arteries (blood vessels) that, over time, adds significantly to the risk of heart disease, heart attacks, and stroke. Semaglutide supplementation reduces this buildup.
- Limiting systemic inflammation. Through the same mechanism described above that Semaglutide uses to reduce atherosclerosis, it also tamps down systemic inflammation. Long-term inflammation is associated with multiple age-related chronic diseases, from cardiovascular disease to neurodegenerative conditions such as Alzheimer’s to arthritis. Along with other dietary and lifestyle practices to reduce chronic inflammation, Semaglutide can help to stave off these illnesses.
- Lowered insulin resistance. Maintaining insulin sensitivity (how effectively cells respond to insulin) is critical for long-term metabolic health. Semaglutide, in addition to lowering body weight, also reduces insulin resistance (the opposite of insulin sensitivity).
- Protected cognitive function. Postprandial plasma glucose refers to blood sugar levels following food intake, which tend to increase (especially after carb-heavy meals).
Undesirably high PPG levels are associated with cognitive decline:
“PPG [postprandial plasma glucose] excursion is associated with a decline in cognitive functioning and that a tighter control of PPG may prevent cognitive decline.”
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) – a class of drugs that Semaglutide belongs to — have been shown to “ to reduced glucose reabsorption and subsequent reductions in PPG.”
This supports the use of Semaglutide to slow or possibly prevent age-related cognitive decline by limiting PPG.
- Lowered harmful triglyceride and LDL cholesterol levels. There is a documented correlation between PPG and LDL cholesterol levels — higher PPG leads to higher LDL levels. Because Semaglutide reduces PPG, it also produces significant reductions in triglycerides (TG) as well as very‐low‐density‐lipoprotein (VLDL), the two most dangerous types of cholesterol for heart health: “fasting concentrations of TG and VLDL were… significantly lower with Semaglutide than with placebo.”
- “Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics.” Accessed via https://pubmed.ncbi.nlm.nih.gov/16864814/
- “Postprandial plasma glucose excursion is associated with an atherogenic lipid profile in individuals with type 2 diabetes mellitus: A cross-sectional study.” Accessed via https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258771
- “A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.” Accessed via https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.12998
- “The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways.” Accessed via https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314963/
- “Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide.” Accessed via https://pubmed.ncbi.nlm.nih.gov/30938762/
- “Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity.” Accessed via https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836914/